Government regulation strategy, leading firms' innovation strategy, and following firms imitation strategy: An analysis based on evolutionary game theory.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 11 01 2023
accepted: 22 05 2023
medline: 12 6 2023
pubmed: 8 6 2023
entrez: 8 6 2023
Statut: epublish

Résumé

In the innovation ecosystem, the knowledge-based game behavior of each subject not only pertains to its own survival and development but also affects evolution of the innovation ecosystem. The present study investigates the choice of government's regulation strategy, leading firms' innovation protection strategy and following firms' imitation strategy from the perspective of group evolutionary game. Based on the cost-benefit perspective, an asymmetric tripartite evolutionary game model and a simulation model are constructed to analyze the strategies and stability of the evolutionary equilibrium of each subject. We focus mainly on the protection intensity of innovation achievements by leading enterprises and the difficulty of imitation and substitution by following enterprises. The cost of patent operation and maintenance, government subsidies, and the relative difficulty of technology substitution and imitation were identified as the key factors affecting the evolutionary equilibrium of the system. Based on different scenarios resulting from the aforementioned factors, four equilibrium states are observed in the system, namely {no government regulation, technology secrecy, substitution}, {no government regulation, technology secrecy, imitation}, {no government regulation, patent application, imitation}, and {government regulation, patent application, imitation}. Finally, the study suggests corresponding recommendations for the three parties, which can help governments as well as the leading and following firms to choose appropriate behavioral strategies. At the same time, this study offers positive insights to participants in the global innovation ecosystem.

Identifiants

pubmed: 37289768
doi: 10.1371/journal.pone.0286730
pii: PONE-D-23-00893
pmc: PMC10249874
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0286730

Informations de copyright

Copyright: © 2023 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors declare that there are no competing interests.

Références

Phys Rev Lett. 2005 Aug 26;95(9):098104
pubmed: 16197256
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13391-4
pubmed: 15329411
Harv Bus Rev. 1993 May-Jun;71(3):75-86
pubmed: 10126156
Science. 2005 Jul 1;309(5731):93
pubmed: 15994539
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10952-5
pubmed: 16829575
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2291-4
pubmed: 18287081
Nature. 2017 Apr 13;544(7649):227-230
pubmed: 28355181
J Theor Biol. 2017 Feb 21;415:1-12
pubmed: 27915074
Nature. 2005 Jan 20;433(7023):312-6
pubmed: 15662424
Phys Rev E Stat Nonlin Soft Matter Phys. 2002 Dec;66(6 Pt 1):062903
pubmed: 12513331
J Theor Biol. 1964 Jul;7(1):17-52
pubmed: 5875340
Phys Life Rev. 2014 Dec;11(4):573-86
pubmed: 24613645
Nature. 2007 Aug 30;448(7157):1046-9
pubmed: 17728757
Biosystems. 2010 Feb;99(2):109-25
pubmed: 19837129
Nature. 2004 Nov 25;432(7016):499-502
pubmed: 15565153

Auteurs

Mengke Zhang (M)

School of Management, Beijing Union University, Beijing, China.

Yan Huang (Y)

School of Management, Beijing Union University, Beijing, China.

Yifan Jin (Y)

School of Management, Beijing Union University, Beijing, China.

Yuan Bao (Y)

School of Management, Beijing Union University, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH